Skip to main content
main-content
Top

06-14-2018 | Pioglitazone | Article

Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies

Journal: Diabetology International

Authors: Juha Mehtälä, Houssem Khanfir, Dimitri Bennett, Yizhou Ye, Pasi Korhonen, Fabian Hoti

Publisher: Springer Japan

share
SHARE

Abstract

Background

Studies investigating bladder cancer risk in pioglitazone-treated type 2 diabetes mellitus patients report conflicting results. Previous meta-analyses on this topic utilized publications prior to 2013. More long-term observational studies have been published since then. We reviewed the accumulated evidence and updated findings from previous meta-analyses.

Methods

This meta-analysis was based on a systematic review of peer-reviewed observational studies published prior to September 30, 2016. Eligible studies were identified using a specified MEDLINE search. References from included studies and from previous meta-analyses were screened for additional records. Meta-analysis hazards ratios were derived using a random-effects model. Several sensitivity analyses including hierarchical Bayesian meta-analysis with country-specific effects were conducted.

Results

Of 363 identified records, 23 studies were included in this review and 18 in the actual meta-analyses. For bladder cancer outcome, the estimated effect size for ever vs. never use of pioglitazone was 1.16 [95% confidence interval (CI), 1.04–1.28]. In the cumulative dose and duration analyses, highest effect was observed in the highest/longest exposure group, but substantial heterogeneity was present. In the sensitivity analysis, only studies adjusted for lifestyle-related factors were included and the frequentist effect size was 1.18 (95% CI, 1.00–1.40, p = 0.054). However, the risk was not verified in the Bayesian framework with an effect size of 1.17 [95% credible interval (CrI), 0.94–1.54].

Conclusions

In line with previous meta-analyses, we observed a small but statistically significant association between ever (vs. never) use of pioglitazone and bladder cancer risk; however, causality is not established and alternative explanations cannot be ruled out.
Literature
1.
World Health Organization. Global Report on Diabetes. 2016. http://​apps.​who.​int/​iris/​bitstream/​10665/​204871/​1/​9789241565257_​eng.​pdf?​ua=​1. Accessed 23 Aug 2016.
2.
Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. http://​www.​cdc.​gov/​diabetes/​pubs/​statsreport14/​national-diabetes-report-web.​pdf. Accessed 23 Aug 2016.
3.
American Diabetes Association. Economic Costs of Diabetes in the US in 2012. Diabetes Care. 2013;36:1033–46. https://​doi.​org/​10.​2337/​dc12-2625. CrossRefPubMedCentral
4.
DeFronzo RA, Banerji M, Bray GA, et al. Actos now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009. https://​doi.​org/​10.​1186/​1472-6823-9-17. CrossRefPubMedPubMedCentral
5.
DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15. https://​doi.​org/​10.​1056/​NEJMoa1010949. CrossRefPubMed
6.
Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10–7. CrossRefPubMed
7.
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22:1395–409. CrossRefPubMed
8.
Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251–7. PubMed
9.
Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, Randomized Trial. J Clin Endocrinol Metab. 2004;89:6068–76. https://​doi.​org/​10.​1210/​jc.​2003-030861. CrossRefPubMed
10.
Takeda Pharmaceuticals America, Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. 2009. http://​www.​actos.​com/​actospro/​home.​aspx. Accessed 12 Aug 2016.
11.
Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369–71. https://​doi.​org/​10.​2337/​dc10-2412. CrossRefPubMedPubMedCentral
12.
Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916–22. https://​doi.​org/​10.​2337/​dc10-1068. CrossRefPubMedPubMedCentral
13.
Tseng C-H. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278–80. https://​doi.​org/​10.​2337/​dc11-1449. CrossRefPubMedPubMedCentral
14.
Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953–62. https://​doi.​org/​10.​1007/​s00125-012-2538-9. CrossRefPubMedPubMedCentral
15.
Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645. CrossRefPubMedPubMedCentral
16.
Fujimoto K, Hamamoto Y, Honjo S, et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;99:e21–3. https://​doi.​org/​10.​1016/​j.​diabres.​2012.​11.​013. CrossRefPubMed
17.
Song SO, Kim KJ, Lee B-W, et al. The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. Diabetes Metab J. 2012;36:371–8. https://​doi.​org/​10.​4093/​dmj.​2012.​36.​5.​371. CrossRefPubMedPubMedCentral
18.
Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ Can Med Assoc J J Assoc Medicale Can. 2012;184:E675–83. https://​doi.​org/​10.​1503/​cmaj.​112102. CrossRef
19.
Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18:148–56. https://​doi.​org/​10.​1634/​theoncologist.​2012-0302. CrossRefPubMedPubMedCentral
20.
Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30:1026–32. https://​doi.​org/​10.​1111/​dme.​12144. CrossRefPubMed
21.
Turner RM, Kwok CS, Chen-Turner C, et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis: thiazolidinediones and bladder cancer. Br J Clin Pharmacol. 2014;78:258–73. https://​doi.​org/​10.​1111/​bcp.​12306. CrossRefPubMed
22.
Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012;98:159–63. https://​doi.​org/​10.​1016/​j.​diabres.​2012.​05.​006. CrossRefPubMed
23.
He S, Tang Y, Zhao G, et al. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:2095–102. https://​doi.​org/​10.​1007/​s13277-013-1278-x. CrossRef
24.
Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493–504. https://​doi.​org/​10.​1007/​s00125-014-3456-9. CrossRefPubMed
25.
Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265. https://​doi.​org/​10.​1001/​jama.​2015.​7996. CrossRefPubMed
26.
Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541. CrossRefPubMedPubMedCentral
27.
Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ. 2016. https://​doi.​org/​10.​1136/​bmj.​i3903. CrossRefPubMedPubMedCentral
28.
von Hippel PT. The heterogeneity statistic I 2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015. https://​doi.​org/​10.​1186/​s12874-015-0024-z. CrossRef
29.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. https://​doi.​org/​10.​1002/​sim.​1186. CrossRefPubMed
30.
Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. https://​doi.​org/​10.​1136/​bmj.​327.​7414.​557. CrossRefPubMedPubMedCentral
31.
Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol. 2001;54:1046–55. https://​doi.​org/​10.​1016/​S0895-4356(01)00377-8. CrossRefPubMed
32.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101. CrossRefPubMed
33.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. CrossRefPubMedPubMedCentral
34.
Jin S-M, Song SO, Jung CH, et al. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. J Korean Med Sci. 2014;29:238. https://​doi.​org/​10.​3346/​jkms.​2014.​29.​2.​238. CrossRefPubMedPubMedCentral
35.
Hsiao F-Y, Hsieh P-H, Huang W-F, et al. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf. 2013;36:643–9. https://​doi.​org/​10.​1007/​s40264-013-0080-4. CrossRefPubMed
36.
Mackenzie TA, Zaha R, Smith J, et al. Diabetes pharmacotherapies and bladder cancer: a medicare epidemiologic study. Diabetes Ther. 2016;7:61–73. https://​doi.​org/​10.​1007/​s13300-016-0152-4. CrossRefPubMedPubMedCentral
37.
Shapiro S. Causation, bias and confounding: a hitchhiker’s guide to the epidemiological galaxy part 2. Principles of causality in epidemiological research: confounding, effect modification and strength of association. J Fam Plann Reprod Health Care. 2008;34:185–90. https://​doi.​org/​10.​1783/​1471189087847348​73. CrossRefPubMed
38.
Greco T, Zangrillo A, Biondi-Zoccai G, et al. Meta-analysis: pitfalls and hints. Heart Lung Vessels. 2013;5:219–25. PubMedPubMedCentral
39.
Chang C-H, Lin J-W, Wu L-C, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55:1462–72. https://​doi.​org/​10.​1002/​hep.​25509. CrossRefPubMed
40.
Kuo H-W, Tiao M-M, Ho S-C, et al. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci. 2014;30:94–7. https://​doi.​org/​10.​1016/​j.​kjms.​2013.​09.​011. CrossRefPubMed
41.
Han E, Jang S-Y, Kim G, et al. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine (Baltimore). 2016;95:e2786. https://​doi.​org/​10.​1097/​MD.​0000000000002786​. CrossRef
42.
Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. JNCI J Natl Cancer Inst. 2012;104:1411–21. https://​doi.​org/​10.​1093/​jnci/​djs328. CrossRefPubMed
43.
Tseng C-H. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278–80. https://​doi.​org/​10.​2337/​dc11-1449. CrossRefPubMedPubMedCentral
44.
Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2013;75:254–9. https://​doi.​org/​10.​1111/​j.​1365-2125.​2012.​04325.​x. CrossRefPubMed
45.
Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig. 2013;33:621–31. https://​doi.​org/​10.​1007/​s40261-013-0106-9. CrossRefPubMedPubMedCentral
46.
Lee M-Y, Hsiao P-J, Yang Y-H, et al. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. PLoS One. 2014;9:e85479. https://​doi.​org/​10.​1371/​journal.​pone.​0085479. CrossRefPubMedPubMedCentral
47.
Balaji V, Seshiah V, Ashtalakshmi G, et al. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab. 2014;18:425. https://​doi.​org/​10.​4103/​2230-8210.​131223. CrossRefPubMedPubMedCentral
48.
Lewis JD, Habel L, Quesenberry C, et al. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer: proteinuria and bladder cancer diagnosis. Pharmacoepidemiol Drug Saf. 2014;23:636–45. https://​doi.​org/​10.​1002/​pds.​3619. CrossRefPubMed

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions